You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Interactive technology for media literacy drug prevention in community groups

    SBC: REAL PREVENTION LLC            Topic: NIDA

    The goals of this Phase II STTR are to evaluate the outcomes of REAL mediaan interactiveselfpacede learning substance use prevention media literacy curriculum and prepare it for marketing to community organizationsincluding our partnerHSubstance use increases in frequency and risk through mid adolescenceyet prevention interventions primarily target early useare time intensiveand are implemented in ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    Polo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Soluble E NTPDase for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIGMS

    SUMMARY Sepsis is a medical condition caused by an overwhelming systemic inflammatory response to infection Although the underlying infection can now be efficiently treated with antibiotics there are no effective therapies to control the organ damage caused by the inflammatory response of the host As a result sepsis is the leading cause of mortality in intensive care units and is the tenth lea ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel Scaffold to Promote Skin Regeneration

    SBC: FirstString Research, Inc            Topic: NIAMS

    PROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. A practical and versatile high resolution D dosimetry system for clinical use

    SBC: HEURIS INC.            Topic: 102

    Quality assurance QA is a critical component of radiation oncology that ensures both effective treatment delivery and patient safety Over the last decade dQA is now particularly important asramatic innovations in treatment delivery technologiesy have led to increasingly sophisticated and complex treatments that are difficult to adequately verify with conventional dosimetric verification system ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Telehealth Intervention for Improved Blood Pressure Control with Targeted Incentives Using New Technologies and Insights From Behavioral Economics to Increase the Effectiveness of Behavioral Change

    SBC: Wellth Inc.            Topic: NIA

    PROJECT SUMMARY ABSTRACT Hypertension or sustained systolic and diastolic blood pressure BP of and mm Hg or higher is among the most frequently encountered conditions in primary care in the U S The estimated prevalence is among all U S adults and increases with age to affect of seniors Hypertension is also the leading risk factor for cardiovascular disease global mortality ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Small Molecule Therapy for the Treatment of Heart Failure

    SBC: SUMOCOR LLC            Topic: NHLBI

    ABSTRACT The incidence of heart failure HF continues to increase in the United States despite significant advances in pharmacological therapies and novel devices There is an acute need for novel treatment strategies for heart failure A key abnormality in HF is defective handling of calcium that has been partially related to abnormal sarcoplasmic reticulum SR function in cardiac myocytes Red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Dental Adhesives to Prevent Recurrent Caries

    SBC: CuRE Innovations, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Bacterial related marginal decay is the top reason for failure and retreatment of resin based composite restorations RBCs Retreatment of these restorations costs both the patients and insurance companies billions of dollars per year The weak point of the system is the zone known as the hybrid layer where the adhesive bonds the RBC to the dentin There are ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Novel mechanism for the treatment of epilepsy: New Vitamin K analogs target energetics and have low toxicity due to excellent specificity and low dose requirements compared to current therapies

    SBC: NEUROENE THERAPEUTICS INC            Topic: 106

    DESCRIPTION provided by applicant Epilepsy is the th most common neurological disorder with in people developing epilepsy the occurrence of more than one unprovoked seizure at some point in their lifetime Unfortunately of all patients have intractable medication resistant epilepsy Thus new anti epileptic drugs AEDs that target alternative mechanisms of action are needed ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government